UP-3.068: The Risk Factors Increasing Post Void Residual Urine Volume after Long-Term Anticholinergics Therapy Over 1 Year in Patients with Benign Prostatic Hyperplasia Accompanied with Overactive Bladder

Urology ◽  
2009 ◽  
Vol 74 (4) ◽  
pp. S315
Author(s):  
I. Cho ◽  
H. Song ◽  
S. Cho ◽  
K. Lee ◽  
J. Chung ◽  
...  
Keyword(s):  
Risk Factors ◽  
Benign Prostatic Hyperplasia ◽  
Overactive Bladder ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Residual Urine Volume ◽  
Residual Urine

scholarly journals 15 years’ survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression

2018 ◽  
Vol 86 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Andrey Zinovievich Vinarov ◽  
Leonid Grigorievich Spivak ◽  
Darina Vladimirovna Platonova ◽  
Leonid Mikhailovich Rapoport ◽  
Dmitry Olegovich Korolev
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Plant Extract ◽  
Prostate Volume ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Term Therapy ◽  
Serenoa Repens ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Study Results

Aim: The aim of this study is to investigate the efficacy and safety of long-term therapy with Serenoa repens extract with regard to halting benign prostatic hyperplasia progression. Material and methods: An open non-comparative observational study of the continuous use of S. repens plant extract at a dosage of 320 mg once a day for 15 years was performed in 30 patients at risk for benign prostatic hyperplasia progression. Changes in IPSS (International Prostatic Symptoms Scale) and QoL (Quality of life) scores and changes in Qmax, voided volume, residual urine volume, and prostate volume were evaluated during the study. Results: The study showed an absence of progression based on both subjective (the sum of scores on the IPSS and QoL scales) and objective (prostate volume, urination rate, residual urine volume) criteria. Furthermore, the patients had no adverse events related to the study drug, including prostate cancer. Conclusions: The 15 years’ study results suggest that taking S. repens plant extract continuously at a daily dose of 320 mg is an effective and safe way to prevent the progression of benign prostatic hyperplasia.

scholarly journals Evaluation of ayurvedic therapy in management of Benign Prostatic Hyperplasia

2019 ◽  
Vol 10 (3) ◽  
pp. 2360-2364
Author(s):  
Arun Kumar Dwivedi ◽  
Awadhesh Kumar Pandey
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Urine Volume ◽  
Middle Lobe ◽  
Prostatic Hyperplasia ◽  
Residual Urine Volume ◽  
First Line ◽  
Residual Urine ◽  
Prostate Growth

Benign Prostatic Hyperplasia (BPH) is a common condition that affects 50% of men in their 50 th decade. There have been many advances in the treatment of this condition, which aim to improve the patient’s quality of life.1 Although there is no cure for BPH, but there are many useful options for treating the problem. Treatment focuses on prostate growth, which is the cause of BPH symptoms. Once prostate growth starts, it often continues unless treatment starts. The prostate grows in two different ways-in one type of growth, cell multiply around the urethra and squeeze it whereas in the second type of growth is middle lobe prostate growth in which cell grow into the urethra and the bladder outlet area. This type of prostate growth typically requires surgery. The first line of care for treating BPH is often medication.2   Efficacy of Vasti therapy an Ayurvedic therapeutic procedure was studied in 75 patients of Benign Prostatic Hyperplasia (BPH). The treatment was given for 21 days, and then the effect was assessed clinically and objectively. Objective observations include determination of size (weight) of prostate and residual urine in the urinary bladder by ultrasonography, estimation of blood urea, serum creatinine and routine, microscopic and microbiological study of urine was also done. After the therapy in 70.67% of 75 patients, the size of the prostate was found regressed, and in 82.14% of 56 patients, the residual urine volume was decreased along with other objective and subjective improvement.

Post-Void Residual Urine Volume is Not a Good Predictor of the Need for Invasive Therapy Among Patients With Benign Prostatic Hyperplasia

2006 ◽  
Vol 175 (1) ◽  
pp. 213???216
Author(s):  
C. A. Mochtar ◽  
L. A. L. M. Kiemeney ◽  
M. M. van Riemsdijk ◽  
M. P. Laguna ◽  
F. M. J. Debruyne ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Good Predictor ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Residual Urine Volume ◽  
Invasive Therapy ◽  
Residual Urine

Post-Void Residual Urine Volume is Not a Good Predictor of the Need for Invasive Therapy Among Patients With Benign Prostatic Hyperplasia

2006 ◽  
Vol 175 (1) ◽  
pp. 213-216 ◽  
Author(s):  
C.A. Mochtar ◽  
L.A.L.M. Kiemeney ◽  
M.M. van Riemsdijk ◽  
M.P. Laguna ◽  
F.M.J. Debruyne ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Good Predictor ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Residual Urine Volume ◽  
Invasive Therapy ◽  
Residual Urine

scholarly journals Safety and efficacy of prostatic artery embolization for large benign prostatic hyperplasia in elderly patients

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098628
Author(s):  
Chen Xu ◽  
Gang Zhang ◽  
Jin-jin Wang ◽  
Chun-xian Zhou ◽  
Min-jun Jiang
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Elderly Patients ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Antigen Level ◽  
Residual Urine Volume ◽  
Safety And Efficacy ◽  
Total Prostate Specific Antigen

Objective To assess the safety and efficacy of prostatic arterial embolization (PAE) for elderly patients with lower urinary tract symptoms secondary to large benign prostatic hyperplasia. Methods Twenty-eight patients (>80 years of age) with prostate volume >80 mL were enrolled from October 2016 to October 2019. PAE was performed using microspheres and functional results were evaluated at 1, 3, 6, and 12 months postoperatively. The following data were recorded: International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urine flow rate (Qmax), post-void residual urine volume, prostate volume and total prostate-specific antigen level. Results Selective prostatic arterial catheterization and embolization were achieved in 27 of 28 patients. Follow-up data were available for those 27 patients until 12 months postoperatively. Significant improvements were found at all postoperative time points in terms of the mean IPSS, mean QoL score, mean Qmax, mean post-void residual urine volume, mean total prostate-specific antigen level, and mean prostate volume. The overall complication rate was 46.4%. Conclusions PAE is an efficacious and safe treatment for elderly patients with large prostate volume; it may offer an effective approach for patients who are not candidates for open or endoscopic surgical procedures because of comorbidities.

Sign in / Sign up

Export Citation Format

Share Document